HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mibelle Looks To Maintain Momentum In Plant Stem Cells

This article was originally published in The Rose Sheet

Executive Summary

Mibelle’s R&D team has been working to expand the company’s actives portfolio and capitalize on the popularity of plant stem cells that can fend off the signs of aging.

You may also be interested in...

FDA Warnings Slow, But Anti-Aging Claims Remain Class Action Targets

The online universe is abuzz with complaints about 2016, with some ready to dub the year “worst ever.” It certainly was a rough one for anti-aging skin-care marketers, and while FDA’s warning letter activity has declined of late, consumer lawsuits continue to file challenging companies’ clock-reversing promises.

MyChelle Courts Consumers With Sensitive Skin, Hyperpigmentation

MyChelle Dermaceuticals’ new Pure Harmony range is formulated with moisturizers, anti-inflammatory ingredients and potent actives to address aging and over-treated skin.

In Brief

The House Energy & Commerce Committee names Rep Marsha Blackburn, R-Tenn, as its vice chair. More news in brief.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts